Mesoblast Limited reported a 44% increase in net revenue from sales of its product Ryoncil to US$28 million for the first fiscal quarter ended September 30, compared with US$19 million in the prior year period. Net operational cash spend improved by 85% to US$2.3 million versus US$14.9 million previously. The company cited strong patient adoption across onboarded sites and a robust cash position of US$99 million at quarter-end. Mesobblast operates as a global leader in developing allogeneic cellular medicines for inflammatory diseases.
